More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1538487
EPS
-2.24
P/E ratio
--
Price to sales
0.01
Dividend yield
--
Beta
1.593248
Previous close
$0.09
Today's open
--
Day's range
--
52 week range
$0.08 - $4.69
show more
CEO
Edward A. Pesicka
Employees
6500
Headquarters
Glen Allen, VA
Exchange
OTCID
Shares outstanding
76924334
Issue type
Common Stock
Healthcare
Medical Distributors
Accendra Health Receives Delisting Notice From the New York Stock Exchange
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it received notification from the New York Stock Exchange (“NYSE”) on November 16, 2026, informing it that trading of the Company's common stock on the NYSE was suspended, effective immediately, and that the NYSE has determined to commence proceedings to delist the Company's common stock. The NYSE reached its decision to delist the Company's common stock pursuant to Rule 802.01D of the NYSE Li.
Business Wire • Nov 17, 2026

BLUE SHIELD OF CALIFORNIA EXPANDS COLLABORATION WITH ACCENDRA HEALTH TO IMPROVE ACCESS TO HOME-BASED CARE
OAKLAND, Calif., Nov. 16, 2026 /PRNewswire/ -- Blue Shield of California today announced an expanded collaboration with Accendra Health brands, including Apria and Byram, that integrates durable medical equipment (DME) ordering and referral management into physicians' clinical workflows to improve access to home-based care and to deliver savings for members.
PRNewsWire • Nov 16, 2026

NYSE to Commence Delisting Proceedings Against Accendra Health, Inc. (ACH)
NEW YORK--(BUSINESS WIRE)--The New York Stock Exchange (“NYSE”, the “Exchange”) announced today that the staff of NYSE Regulation has determined to commence proceedings to delist the common stock — ticker symbol ACH —of Accendra Health, Inc. (the “Company”) from the NYSE. Trading in the Company's common stock will be suspended immediately. NYSE Regulation has determined that the Company's common stock is no longer suitable for listing based on “abnormally low selling price” levels, pursuant to.
Business Wire • Nov 16, 2026

Accendra Health, Inc. (ACH) Q3 2026 Earnings Call Transcript
Accendra Health, Inc. ( ACH ) Q3 2026 Earnings Call November 5, 2026 5:00 PM EST Company Participants Will Parrish - VP of Strategy, Corporate Development, & IR Kenneth Gardner-Smith - President, CEO & Director Jonathan Leon - Executive VP, CFO & Corporate Treasurer Conference Call Participants Rishi Parekh - JPMorgan Chase & Co, Research Division Presentation Operator Good evening, and thank you for standing by. Welcome to Accendra Health's Third Quarter 2026 Earnings Conference Call.
Seeking Alpha • Nov 6, 2026

Accendra Health Reports Third Quarter 2026 Financial Results
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today reported financial results for the third quarter ended September 30, 2026. Unless otherwise noted, the results herein reflect the Company's continuing operations, which represent what was previously the Patient Direct segment and certain functional operations. “Over the several weeks since I started, a number of themes have become clear to me. We have strong brands, favorable end markets, and a teammate popula.
Business Wire • Nov 5, 2026

Accendra Health Announces Extension of $150 Million Receivables Sale Program To 2029
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) today announced that it executed an amendment to its Receivables Purchase Agreement (the “Receivables Sale Program”) on October 29, 2026. The amendment, among other things, extends the Scheduled Termination Date of the facility to October 2029, and the $150 million size of the Receivables Sale Program is unchanged. “We are pleased to have worked with our banking partner to extend the Receivables Sale Program until.
Business Wire • Nov 2, 2026

Accendra Health Receives Continued Listing Standard Notice from NYSE Regarding Market Capitalization and Stockholders' Equity; Intends to Submit Business Plan and Return to Compliance with NYSE Listing Standard
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 27, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with Section 802.01B of the NYSE's continued listing standards that the Company have an average market capitalization of not less than $50.0 million over a consecutive 30 trading-day period and stockholders' equity of not less than $50.0 millio.
Business Wire • Oct 30, 2026

Accendra Health Announces Third Quarter 2026 Earnings Release Date and Conference Call
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the “Company”) plans to release financial results for the third quarter of 2026 on Thursday, November 5, 2026, after trading ends on the New York Stock Exchange.The Company will host a conference call for investors and analysts at 5:00 p.m. EST on the same day. Participants may access the call via the toll-free dial-in number at 1-833-461-5787, or the toll dial-in number at 1-585-542-9983. The conference ID access code is 829 856.
Business Wire • Oct 22, 2026

Accendra Health Receives Continued Listing Standard Notice from NYSE; Intends to Cure Deficiency and Return to Compliance with NYSE Listing Standard
RICHMOND, Va.--(BUSINESS WIRE)--Accendra Health, Inc. (NYSE: ACH) (the Company) today announced that on October 6, 2026, it received a notice (the “Notice”) from the New York Stock Exchange (the “NYSE”) notifying the Company that it is not in compliance with the NYSE's continued listing standards because the average closing price of the Company's Class A Common Stock (the “Common Stock”) was less than $1.00 per share over a consecutive 30 trading-day period. The Notice does not result in the im.
Business Wire • Oct 9, 2026

New Strong Sell Stocks for October 9th
ACH, ARDX and DPRO have been added to the Zacks Rank #5 (Strong Sell) List on October 9th, 2026.
Zacks Investment Research • Oct 9, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Accendra Health Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.